Why a Portfolio Purity Claim Is a Prompt, Not Proof
When a supplier lists a material as “typically ≥99%” by HPLC, the phrase is best read as a portfolio-level description, not a stand-alone batch record. It tells a laboratory researcher or materials manager that high purity is the supplier’s usual expectation; it does not tell you which vial is in front of you, which certificate applies to it, or what the certificate actually reports. Research Sciences publishes headline wording such as “≥99% Verified Purity” and “UK Research Materials Over 99.1% Purity” on its homepage, while its FAQs describe peptides as typically supplied at ≥99% purity by HPLC and say the exact purity is stated on the CoA. Those are published statements to reconfirm against the live site and, more importantly, against the specific batch CoA. They should not be inserted into an audit file as if they were a result for the delivered material.
A documented materials audit needs to distinguish between a catalogue claim, a product-page claim and a batch-specific analytical record. The first two help with supplier comparison and purchasing decisions; the third supports traceability. If the audit concerns an item such as Tesamorelin 5mg, TB-500 5mg, Ipamorelin 5mg, CJC-1295 (No DAC) 5mg, GHK-Cu 50mg, BPC-157 10mg, MT-1 10mg or a laboratory accessory, the key question is not whether the website says “≥99%” in general. It is whether the CoA that accompanies that specific batch states the purity result, the identity result and any contaminant screening that the supplier says it performs, and whether all of those details match the label and order record.
The same caution applies to supporting claims. The homepage lists “CoAs Janoshik Analytical Reports”, “3,000+ UK Orders” and “24hr UK Delivery”, but an audit should treat these as current published wording that needs reconfirming at the time of purchase and in the batch documentation. A marketing figure is not a substitute for opening the CoA that accompanies the vial. The phrase “typically ≥99%” should therefore trigger a simple audit reflex: show me the batch, show me the certificate, and show me how the figures align. The materials remain research-use-only and are not for human or veterinary use.
Confirm the Batch Identity, the CoA and the Analytical Scope
The first practical step is to match the physical item to its paperwork. Record the product name, SKU code, stated strength, label reference and expiry date exactly as they appear. Research Sciences explains that its vial labels use a reference format combining SKU code and expiry date, for example BPC10-03/27, linking to the corresponding CoA. That reference should be quoted in any query to the shop and copied into the audit record. Confirm that the CoA names the same product, the same strength and the same reference; a certificate for a related catalogue item is not interchangeable with a batch record for the delivered material.
Second, read the HPLC figure in context. A “typically ≥99%” statement should prompt you to confirm what the CoA actually reports: the actual purity value for that batch, how the value is expressed, and whether the certificate also addresses identity. The shop’s FAQs say every compound includes a CoA (HPLC) for purity and identity, and that independently tested compounds are supported by batch-level analytical verification. The audit should verify those points on the document rather than infer them from the word “HPLC” alone. If the CoA includes additional contaminant screening, such as heavy metals or endotoxin evaluation where the supplier’s testing framework describes it, record exactly what is reported and avoid adding limits, methods or conclusions that are not on the certificate.
Do not let one percentage carry the whole file
A purity percentage is not a complete identity profile, a contaminant screening outcome or a handling record. For audit purposes, separate the questions: what is it? how pure is this batch? what else was tested? how should it be stored? and which document proves it? If a CoA is missing a field you need, record the gap and ask the supplier to clarify using the label reference. Do not fill the gap with a homepage claim or a figure from a different product. The materials are for controlled in-vitro laboratory research only and are not for human or veterinary use.
Audit the Supporting Trail: ITRs, Branding, Storage and Current Terms
A documented audit also needs to catch the quieter mismatches. Research Sciences’ FAQs explain that restocked products may carry the same Internal Test Reference (ITR) as earlier stock. An ITR links to associated sample testing reports, but it does not confirm that separate deliveries come from the same production lot or have had separate independent testing. When you see an ITR in the paperwork, confirm what it actually links to and whether the CoA is batch-specific to the delivery. Do not treat a shared ITR as proof of lot continuity. Similarly, vial cap colours and other packaging may vary; cap colour is not an indicator of identity, analytical quality or manufacturing origin. Record the label reference and CoA alignment instead.
Brand history can also appear in an audit trail. The shop is Research Sciences, while some older pages and blog posts still use Imperial Sciences UK or Imperial Peptides UK. The FAQs describe Research Sciences as the parent company of Imperial Peptides UK and say Imperial Peptides UK continues to operate as a brand. If historical documents carry an older brand name, clarify the relationship from the supplier’s published FAQ rather than assuming a different source. Then attach the clarification to the audit record alongside the batch CoA. For current catalogue review, the Buy peptides category page can act as an index, but the individual product page and its batch CoA remain the documents to check.
Finally, confirm storage and handling statements in the in-vitro workflow. Lyophilised materials are described for storage at –20°C or below, sealed with desiccant and protected from moisture, heat and light, with reconstituted material less stable and intended for short-term laboratory storage at 2–8°C. If a protocol requires reconstitution for an in-vitro assay, document the diluent volume and concentration in the laboratory record, allow the vial to reach ambient temperature before opening in a clean research setting, and allow the peptide and solvent to reach ambient temperature before reconstitution. Avoid repeated freeze–thaw cycles. These are laboratory handling notes only; the materials are not for human or veterinary use, and any calculator or preparation tool is not for medical or clinical dosing. Keep the audit file factual: quote the supplier’s current published wording where necessary, state that it should be reconfirmed, and anchor every purity statement to the batch CoA rather than to “typically ≥99%”.
From Amman to Montreal, Omar is an aerospace engineer turned culinary storyteller. Expect lucid explainers on hypersonic jets alongside deep dives into Levantine street food. He restores vintage fountain pens, cycles year-round in sub-zero weather, and maintains a spreadsheet of every spice blend he’s ever tasted.